REGENERON PHARMACEUTICALS, INC. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
REGENERON PHARMACEUTICALS, INC. (REGN) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $15.60 million as of 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Notes
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2022-11-03
- 2022-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $15.60M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2022-09-30 | $15.60M 10-Q · filed 2022-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |